Why did Cantargia fall on 6 October?
Written after the close on
Cantargia −4.05%
Cantargia fell sharply in the last session, with no company-specific cause apparent. Over the last five trading days Cantargia was roughly unchanged, while the OMX Stockholm 30 — Stockholm's index of its thirty biggest listed companies — was also roughly flat, so the week's net move was small even though the final session was weak. The company news in the window was preclinical work (lab and animal studies, not yet in patients) supporting nadunolimab combined with RAS-blocking drugs in pancreatic cancer, presented at a cancer research conference last week; that likely kept scientific interest alive but did not lift the shares. The sharp drop likely reflects broad sentiment toward small, loss-making biotech names, where price swings are usually driven by trial timelines, financing needs and shifting risk appetite rather than daily news. What to watch is the planned phase Ib/IIa study of nadunolimab with a RAS inhibitor, since that is the next concrete catalyst the company has flagged.
Earlier this week
Cantargia rose sharply as pancreatic-cancer data lifted its RAS strategy. Over the last five trading days Cantargia climbed clearly, going against a slightly softer Stockholm market, with the strength concentrated in the most recent session. The likely driver was the presentation of preclinical results — laboratory studies, not yet in patients — showing that its antibody nadunolimab combined with a RAS inhibitor shrank tumours and reshaped the tumour environment in pancreatic cancer, reinforcing the scientific case for its planned early-phase clinical trial. That news landed last week, so it plausibly kept feeding demand into the latest session rather than being a same-day event. Cantargia is a small clinical-stage biotech, so its shares typically swing on trial and data milestones rather than on broad market moves, which is why it can rise while the index drifts.